Abbott's Volt PFA System Used in Procedures for Patients with Abnormal Heart Rhytms
By Denny Jacob
Abbott Laboratories disclosed that the first global procedures have been conducted using its new Volt Pulsed Field Ablation system to treat patients battling common abnormal heart rhythms such as atrial fibrillation.
The healthcare-products manufacturer said over 30 patients were treated in Australia as part of its clinical study evaluating the safety and effectiveness of its Volt PFA system. The company expects approval for its U.S. clinical trial for the system in the first half of this year.
Abbott said patients requiring a cardiac ablation procedure to treat conditions like atrial fibrillation received radiofrequency ablation, which uses heat to destroy tissue responsible for erratic heart signals, or cryogenic ablation, which freezes tissue. The company's system uses high-energy electrical impulses to destroy the cells causing abnormal heart rhythms, rather than heat or extreme cold, which it said can reduce the risk of damaging adjacent tissue in patients with complex disease or anatomy.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 18, 2024 09:33 ET (14:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks